Please assess the completion status of the following clinical trial:

Trial Title: Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Age 18 or greater with a confirmed diagnosis of homozygous SCD (HbSS, HbSC, HbSB0), sickle cell trait (HbAS), or healthy volunteer (HbA)~* Normal renal function: creatinine \<1.5 mg/dL~* Negative direct antiglobulin test (DAT)~* Ability to give informed consent to participate in the protocol~EXCLUSION CRITERIA:~* Any uncontrolled chronic illness other than sickle cell disease~* Active viral, bacterial, fungal, or parasitic infection~* Consumption of biotin supplements or raw eggs within 30 days~* Blood loss within the previous 8 weeks \>540mL~* Pregnancy~* Pre-existing, naturally occurring antibodies against biotin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Sickle Cell Disease Pre-Transplantation (Type: EXPERIMENTAL): Autologous cells will be collected in participants with Sickle Cell Disease Pre-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
- Sickle Cell Disease Post-Transplantation (Type: EXPERIMENTAL): Autologous cells will be collected in participants with Sickle Cell Disease Post-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
- Sickle Cell Trait (HbAS) (Type: EXPERIMENTAL): Autologous cells will be collected in participants with Sickle Cell Trait (HbAS) and biotin-labeled ex vivo and reinfused to measure red cell survival
- HbAA (Healthy volunteers) (Type: EXPERIMENTAL): Autologous cells will be collected in participants with HbAA (Healthy volunteers) and biotin-labeled ex vivo and reinfused to measure red cell survival

Based on this trial design, predict the completion outcome and termination type (if applicable).